PMID- 26627200
OWN - NLM
STAT- MEDLINE
DCOM- 20160620
LR  - 20181113
IS  - 1423-0127 (Electronic)
IS  - 1021-7770 (Print)
IS  - 1021-7770 (Linking)
VI  - 22
DP  - 2015 Dec 2
TI  - TGF-beta induces HLA-G expression through inhibiting miR-152 in gastric cancer 
      cells.
PG  - 107
LID - 10.1186/s12929-015-0177-4 [doi]
LID - 107
AB  - BACKGROUND: Mounting evidences have showed the important role of transforming 
      growth factor-beta (TGF-beta) in immunological surveillance of tumors. Some studies 
      have also indicated human leukocyte antigen (HLA)-G-associated immune escape 
      involving TGF-beta management in gastric cancer (GC). However, the mechanism 
      underlying it is unclear. This study aims to verify the correlations between 
      HLA-G and TGF-beta, involving the potential targeting of miR-152 on HLA-G. RESULTS: 
      TGF-beta and HLA-G levels were analyzed in blood samples from twenty GC patients 
      with ELISA assays, while TGF-beta showed directly proportional to HLA-G levels in GC 
      patients, and TGF-beta induced HLA-G up-regulation was also confirmed in GC cell 
      lines. Furthermore, miR-152 expression could be inhibited by TGF-beta, and the 
      negative post-transcriptionally regulation of miR-152 on HLA-G was also 
      demonstrated through gain- and loss-of-function studies. Besides, miR-152 
      overexpression repressed HLA-G up-regulation induced by TGF-beta. And, miR-152 
      expression levels showed inversely proportional to both HLA-G and also TGF-beta 
      levels in GC patients. CONCLUSION: TGF-beta could induce HLA-G expression in GC by 
      inhibiting miR-152, involving its negative regulation on HLA-G. Since TGF-beta 
      induced HLA-G up-regulation plays important role in immune escape, a potential 
      application of miR-152 was suggested in GC treatment, or miR-152 might be one 
      potential biomarker for GC.
FAU - Guan, Zhongzheng
AU  - Guan Z
AD  - Department of General Surgery, Qilu Hospital, Shandong University, No.107, West 
      Wenhua Road, Jinan, Shandong Province, 250012, China.
AD  - Department of General Surgery, Affiliated Hospital of Binzhou Medical University, 
      Binzhou, Shandong, 256603, China.
FAU - Song, Bingtan
AU  - Song B
AD  - Department of General Surgery, Qilu Hospital, Shandong University, No.107, West 
      Wenhua Road, Jinan, Shandong Province, 250012, China.
AD  - Department of General Surgery, Liaocheng Third People's Hospital, Liaocheng, 
      Shandong, 252000, China.
FAU - Liu, Fengjun
AU  - Liu F
AD  - Department of General Surgery, Qilu Hospital, Shandong University, No.107, West 
      Wenhua Road, Jinan, Shandong Province, 250012, China. fengjliuj@163.com.
FAU - Sun, Dong
AU  - Sun D
AD  - Department of General Surgery, Qilu Hospital, Shandong University, No.107, West 
      Wenhua Road, Jinan, Shandong Province, 250012, China.
FAU - Wang, Kexin
AU  - Wang K
AD  - Department of General Surgery, Qilu Hospital, Shandong University, No.107, West 
      Wenhua Road, Jinan, Shandong Province, 250012, China.
FAU - Qu, Hui
AU  - Qu H
AD  - Department of General Surgery, Qilu Hospital, Shandong University, No.107, West 
      Wenhua Road, Jinan, Shandong Province, 250012, China.
LA  - eng
PT  - Journal Article
DEP - 20151202
PL  - England
TA  - J Biomed Sci
JT  - Journal of biomedical science
JID - 9421567
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA-G Antigens)
RN  - 0 (MIRN152 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (RNA, Neoplasm)
RN  - 0 (Transforming Growth Factor beta)
SB  - IM
MH  - Biomarkers, Tumor/*biosynthesis/genetics/immunology
MH  - Cell Line, Tumor
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - HLA-G Antigens/*biosynthesis/genetics/immunology
MH  - Humans
MH  - Male
MH  - MicroRNAs/*biosynthesis/genetics/immunology
MH  - Neoplasm Proteins/*biosynthesis/genetics/immunology
MH  - RNA, Neoplasm/*biosynthesis/genetics/immunology
MH  - Stomach Neoplasms/genetics/immunology/*metabolism/pathology
MH  - Transforming Growth Factor beta/genetics/immunology/*metabolism
MH  - Tumor Escape/genetics
PMC - PMC4667479
EDAT- 2015/12/03 06:00
MHDA- 2016/06/21 06:00
PMCR- 2015/12/02
CRDT- 2015/12/03 06:00
PHST- 2015/04/25 00:00 [received]
PHST- 2015/08/05 00:00 [accepted]
PHST- 2015/12/03 06:00 [entrez]
PHST- 2015/12/03 06:00 [pubmed]
PHST- 2016/06/21 06:00 [medline]
PHST- 2015/12/02 00:00 [pmc-release]
AID - 10.1186/s12929-015-0177-4 [pii]
AID - 177 [pii]
AID - 10.1186/s12929-015-0177-4 [doi]
PST - epublish
SO  - J Biomed Sci. 2015 Dec 2;22:107. doi: 10.1186/s12929-015-0177-4.